Assessment of an Automatic Closed-loop Insulin Delivery System

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall aim of this research proposal is to determine the safety, feasibility and efficacy of an automatic closed-loop insulin delivery system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery

NCT01492062

Type 1 Diabetes Mellitus

WITHDRAWN NA

Clinical Startup of the 670G Closed Loop Insulin Delivery System

NCT03017482

Diabetes Mellitus, Type 1

COMPLETED

Multiday Fully Closed Loop Insulin Delivery in Monitored Outpatient Conditions

NCT02127827

To Demonstrate That the Closed Loop System Can be Used Safely Over a Few Consecutive Days. To Assess Effectiveness in Maintaining Patients' Glucose Levels in the Target Range of 70 to 180 mg/dl, Measured by Blood Glucose Sensor. To Evaluate the User Experience With a Closed Loop System

UNKNOWN NA

Cross-over Study to Evaluate the Safety and Efficacy of Night Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy in Poorly Controlled Patients With Type 1 Diabetes

NCT02733211

Type 1 Diabetes

WITHDRAWN NA

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317

Type 1 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be completed in two parts.

The initial part of this study will be an inpatient evaluation of the system with the primary goal of assessing safety and feasibility. This will involve 8 subjects with type 1 diabetes, aged 14 - 40 years, admitted for up to 60 hour. Plasma glucose levels will be collected hourly and tested by YSI (YSI 2300, Yellow Springs Instrument). These studies will be performed at Stanford University and will include group sporting activities to mimic the diabetes camp environment. Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise, and prebed by subjects with research staff supervision during the day and at 00:00, 03:00 and 07:00 by research staff. These data will be reviewed by the DSMB before proceeding to camp studies.

The second part of this study will be to test the efficacy of the system during diabetes summer camps. We will test the system in subjects with type 1 diabetes, aged 14-40 years, attending diabetes camp. There will be 20 subjects recruited, with 10 subjects randomized to the control arm Medtronic 530G system with threshold suspend (control group) and 10 subjects randomized to the automatic closed-loop insulin delivery (intervention group). Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise and prebed by subjects with research staff supervision and at 00:00, 03:00 and 07:00 by research staff. The primary aim of this study is to generate preliminary data of system safety and efficacy in a closely supervised environment that challenges glucose control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

automatic closed-loop insulin delivery

The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes

Group Type EXPERIMENTAL

Automatic closed-loop insulin delivery

Intervention Type DEVICE

Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.

Control

The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.

Group Type ACTIVE_COMPARATOR

Control

Intervention Type DEVICE

Threshold suspend

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Automatic closed-loop insulin delivery

Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.

Intervention Type DEVICE

Control

Threshold suspend

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

530G Pump

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Clinical diagnosis of type 1 diabetes

* The diagnosis of type 1 diabetes is based on the investigator's judgment
* C peptide levels and antibody determinations are not required
2. Daily insulin therapy for ≥ 12 months
3. Insulin pump therapy for ≥ 3 months
4. Age 14.0 - 40.0 years
5. Subject comprehends written English
6. Female subjects who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD
7. Female subjects past menarche must have a negative urine pregnancy test
8. Informed consent form is signed by the subject and/or parent and assent assigned by the subject if under 18 years of age
9. For subjects under 18 years, both the subject and parent/guardian understand the study protocol and agree to comply with it. Both parents must sign if possible.

Exclusion Criteria

1. Subject has a medical disorder that in the judgment of the investigator will affect the wearing of the devices or the completion of any aspect of the protocol
2. Diabetic ketoacidosis in the past month
3. Hypoglycemic seizure or loss of consciousness or an event requiring glucagon or IV glucose in the past 3 months
4. Subject has a respiratory condition such as asthma, treated with systemic or inhaled corticosteroids in the previous 6 months or cystic fibrosis
5. Subject has a history of any cardiac or vascular disorder such as myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
6. Subject has a history of liver or kidney disease (other than microalbuminuria)
7. Subject has active Graves' disease
8. Subjects with inadequately treated thyroid disease or celiac disease
9. Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
10. Subject has a history of diagnosed medical eating disorder
11. Subject has a history of known illicit drug abuse
12. Subject has a history of known prescription drug abuse
13. Subject has a history of current alcohol abuse
14. Subject has a history of visual impairment which would not allow subject to participate
15. Subject has an active skin condition that would affect sensor placement
16. Subject has adhesive allergies
17. Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
18. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable)
19. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
20. Subject is currently on beta blocker medication
21. Subject is currently participating in another investigational study (drug or device)
22. Subject is deemed by the investigator to be unwilling or unable to follow the protocol
23. Presence of a febrile illness within 24 hours of enrollment

Minimum Eligible Age

14 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No